Allergy Therapeutics achieve record level of operating profit supported by robust sales
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, has announced its unaudited interim results for the six months ended 31 December 2020. Highlights Financial